Literature DB >> 31093812

Acute Severe Ulcerative Colitis: The Oxford Criteria No Longer Predict In-Hospital Colectomy Rates.

Alice C Moore1, Brian Bressler2.   

Abstract

BACKGROUND: Patients admitted to hospital with acute severe ulcerative colitis have a short-term in-hospital colectomy rate of 30%. The Oxford criteria state that if the CRP is greater than 45 mg/l or there are more than eight bowel movements in 24 h at day 3 of intravenous corticosteroids, there is an 85% risk of an in-hospital colectomy. AIM: The aim of this study was to determine whether this high rate of colectomy continues to be accurate in this medically refractory patient population.
METHODS: We performed a retrospective chart review of 80 patients admitted to a tertiary hospital between 2013 and 2017 with acute severe ulcerative colitis.
RESULTS: Sixteen (20%) patients required an in-hospital colectomy. Of the 33 patients that fulfilled the Oxford criteria, 12 (36%) patients required a colectomy during admission. Only four (9.5%) patients who did not fulfill the Oxford criteria required a colectomy during admission. Twenty-two patients that had fulfilled the Oxford criteria received infliximab as second-line medical therapy.
CONCLUSION: In a patient population that fulfilled the Oxford criteria, the in-hospital colectomy rate has reduced from 85% in 1996 to 36% in 2017. These results should be considered when discussing with patients the opportunity to commence infliximab or cyclosporine as second-line medical therapy.

Entities:  

Keywords:  Biologic therapy; Colectomy; Oxford criteria; Ulcerative colitis

Year:  2019        PMID: 31093812     DOI: 10.1007/s10620-019-05668-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  12 in total

1.  THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS.

Authors:  F C EDWARDS; S C TRUELOVE
Journal:  Gut       Date:  1963-12       Impact factor: 23.059

2.  Cortisone in ulcerative colitis; preliminary report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1954-08-14

Review 3.  The pattern and outcome of acute severe colitis.

Authors:  Lotte C Dinesen; Alissa J Walsh; Marijana Nedeljkovic Protic; Graham Heap; Fraser Cummings; Bryan F Warren; Bruce George; Neil J M Mortensen; Simon P L Travis
Journal:  J Crohns Colitis       Date:  2010-02-19       Impact factor: 9.071

4.  Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years.

Authors:  Ole Hoie; Frank L Wolters; Lene Riis; Tomm Bernklev; Geir Aamodt; Juan Clofent; Epaminondas Tsianos; Marina Beltrami; Selwyn Odes; Pia Munkholm; Morten Vatn; Reinhold W Stockbrügger; Bjorn Moum
Journal:  Gastroenterology       Date:  2006-11-15       Impact factor: 22.682

Review 5.  Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression.

Authors:  Dan Turner; Catharine M Walsh; A Hillary Steinhart; Anne M Griffiths
Journal:  Clin Gastroenterol Hepatol       Date:  2006-12-04       Impact factor: 11.382

6.  Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements.

Authors:  Alain Bitton; Donald Buie; Robert Enns; Brian G Feagan; Jennifer L Jones; John K Marshall; Scott Whittaker; Anne M Griffiths; Remo Panaccione
Journal:  Am J Gastroenterol       Date:  2011-11-22       Impact factor: 10.864

7.  Predicting outcome in severe ulcerative colitis.

Authors:  S P Travis; J M Farrant; C Ricketts; D J Nolan; N M Mortensen; M G Kettlewell; D P Jewell
Journal:  Gut       Date:  1996-06       Impact factor: 23.059

8.  A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations.

Authors:  Ashwin N Ananthakrishnan; Emily L McGinley; David G Binion; Kia Saeian
Journal:  J Gastrointest Surg       Date:  2010-11-25       Impact factor: 3.452

9.  Inaccuracy of patient-reported descriptions of and satisfaction with bowel actions in irritable bowel syndrome.

Authors:  E P Halmos; J R Biesiekierski; E D Newnham; R E Burgell; J G Muir; P R Gibson
Journal:  Neurogastroenterol Motil       Date:  2017-08-10       Impact factor: 3.598

10.  Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis.

Authors:  Elana A Maser; Deepthi Deconda; Simon Lichtiger; Thomas Ullman; Daniel H Present; Asher Kornbluth
Journal:  Clin Gastroenterol Hepatol       Date:  2008-10       Impact factor: 11.382

View more
  5 in total

1.  Concise Commentary: Second Line Is Not Second Best-Continuing Validity of the Oxford Criteria in the Management of Acute Severe Ulcerative Colitis.

Authors:  Pauline Rivière; David Laharie; Philippe Marteau
Journal:  Dig Dis Sci       Date:  2020-02       Impact factor: 3.199

Review 2.  Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel.

Authors:  Parambir S Dulai; Victoria Rai; Laura E Raffals; Dana Lukin; David Hudesman; Gursimran S Kochhar; Oriana M Damas; Jenny S Sauk; Alexander N Levy; M Anthony Sofia; Anne Tuskey; Parakkal Deepak; Andres J Yarur; Anita Afzali; Ashwin N Ananthakrishnan; Raymond K Cross; Stephen B Hanauer; Corey A Siegel
Journal:  Am J Gastroenterol       Date:  2022-04-13       Impact factor: 12.045

Review 3.  Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules.

Authors:  Christine Verdon; Talat Bessissow; Peter L Lakatos
Journal:  J Clin Med       Date:  2019-12-08       Impact factor: 4.241

Review 4.  Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions.

Authors:  Tom Holvoet; Triana Lobaton; Pieter Hindryckx
Journal:  Clin Exp Gastroenterol       Date:  2021-03-08

Review 5.  Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease.

Authors:  Kohei Wagatsuma; Yoshihiro Yokoyama; Hiroshi Nakase
Journal:  Life (Basel)       Date:  2021-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.